一种新型精神活性物质给偏执型精神分裂症的治疗带来了新的挑战。
A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
作者信息
Anderson Caroline, Morrell Christopher, Marchevsky David
机构信息
Milton Keynes Hospital, Milton Keynes, Buckinghamshire, UK.
Campbell Centre, Milton Keynes, UK.
出版信息
BMJ Case Rep. 2015 May 6;2015:bcr2015209573. doi: 10.1136/bcr-2015-209573.
Novel psychoactive substances (NPS), or 'legal highs' are becoming more commonly used as recreational substances in the UK. Their clinical effects are little known and vary considerably between substances. This case discusses a psychiatric inpatient who repeatedly used a stimulant NPS called 'el blanco' while on leave, precipitating relapses of his schizophrenia. The patient initially denied drug use, considering legal highs as different from drugs. The relationship between NPS use and mental state was eventually revealed on careful direct questioning. He recovered and was discharged following treatment with clozapine and education about NPS use. We suggest that specific questioning about NPS usage is added to routine psychiatric history taking and that patients using NPS should be educated about the substances' use.
新型精神活性物质（NPS），即“合法兴奋剂”，在英国正越来越多地被用作消遣性毒品。其临床效果鲜为人知，且不同物质之间差异很大。本病例讨论了一名精神科住院患者，他在休假期间反复使用一种名为“el blanco”的兴奋剂类新型精神活性物质，导致其精神分裂症复发。该患者最初否认吸毒，认为合法兴奋剂与毒品不同。经过仔细的直接询问，最终揭示了使用新型精神活性物质与精神状态之间的关系。他在接受氯氮平治疗并接受有关新型精神活性物质使用的教育后康复出院。我们建议在常规精神科病史采集中增加对新型精神活性物质使用情况的具体询问，并应对使用新型精神活性物质的患者进行有关这些物质使用的教育。
Zotero 插件